A small peptide antagonist of the Fas receptor inhibits neuroinflammation and prevents axon degeneration and retinal ganglion cell death in an inducible mouse model of glaucoma.

Krishnan, Anitha et al.·Journal of neuroinflammation·2019·
RPEP-042922019RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
A small peptide antagonist of the Fas receptor inhibits neuroinflammation and prevents axon degeneration and retinal ganglion cell death in an inducible mouse model of glaucoma.
Published In:
Journal of neuroinflammation, 16(1), 184 (2019)
Database ID:
RPEP-04292

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-04292·https://rethinkpeptides.com/research/RPEP-04292

APA

Krishnan, Anitha; Kocab, Andrew J; Zacks, David N; Marshak-Rothstein, Ann; Gregory-Ksander, Meredith. (2019). A small peptide antagonist of the Fas receptor inhibits neuroinflammation and prevents axon degeneration and retinal ganglion cell death in an inducible mouse model of glaucoma.. Journal of neuroinflammation, 16(1), 184. https://doi.org/10.1186/s12974-019-1576-3

MLA

Krishnan, Anitha, et al. "A small peptide antagonist of the Fas receptor inhibits neuroinflammation and prevents axon degeneration and retinal ganglion cell death in an inducible mouse model of glaucoma.." Journal of neuroinflammation, 2019. https://doi.org/10.1186/s12974-019-1576-3

RethinkPeptides

RethinkPeptides Research Database. "A small peptide antagonist of the Fas receptor inhibits neur..." RPEP-04292. Retrieved from https://rethinkpeptides.com/research/krishnan-2019-a-small-peptide-antagonist

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.